Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 66.00 thousand shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2022-11-14
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2022-09-30 was 0.00 shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2022-06-30 was 50.00K shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2022-03-31 was 16.00K shares, a 94.29% decline year-over-year.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2021-12-31 was 10.00K shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2021 was 290.00K shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2019 was 137.50K shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2017 was 21.15K shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2016 was -506.60K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 50.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 66.00K shares 10-Q · filed 2022-11-14 | 76.00K shares derived: sum of 4 quarters · filed 2022-11-14 | |
| 2022-06-30 | 50.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 66.00K shares 10-Q · filed 2022-08-11 | 76.00K shares derived: sum of 3 quarters · filed 2022-08-11 | 76.00K shares derived: sum of 4 quarters · filed 2022-08-11 | |
| 2022-03-31 | 16.00K shares 10-Q · filed 2022-05-13 | 26.00K shares derived: sum of 2 quarters · filed 2022-05-13 | 26.00K shares derived: sum of 3 quarters · filed 2022-05-13 | 26.00K shares derived: sum of 4 quarters · filed 2022-05-13 | |
| 2021-12-31 | 10.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-07 | 10.00K shares derived: sum of 2 quarters · filed 2022-04-07 | 10.00K shares derived: sum of 3 quarters · filed 2022-04-07 | 290.00K shares 10-K · filed 2022-04-07 | |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 0.00 shares derived: sum of 2 quarters · filed 2021-11-15 | 280.00K shares 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | 280.00K shares 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | 280.00K shares 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | 137.50K shares 10-K · filed 2021-03-25 | ||||
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | 0.00 shares derived: sum of 2 quarters · filed 2019-03-29 | 21.15K shares 10-K · filed 2019-03-29 | -21.15K shares 10-K · filed 2018-04-02 | |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | 21.15K shares 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | 21.15K shares 10-Q · filed 2017-08-08 | ||||
| 2016-12-31 | -506.60K shares 10-K · filed 2018-04-02 | ||||
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | 416.60K shares 10-Q · filed 2016-08-15 | |||
| 2016-03-31 | 416.60K shares 10-Q · filed 2016-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |